Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

This study is testing a drug called brentuximab vedotin in patients with a rare cancer called malignant mesothelioma (a cancer of the lining of the lungs or abdomen) whose tumor cannot be surgically removed and whose cancer cells carry a specific protein called CD30. **You may be eligible if...** - Your mesothelioma has been confirmed to have CD30 on the cancer cells - Your tumor cannot be removed by surgery - You are a woman who is post-menopausal, surgically sterilized, or willing to use reliable contraception - You are a man willing to use contraception during and after treatment - Your general health and organ function meet the required levels for participation **You may NOT be eligible if...** - Your cancer does not have the CD30 protein - You have significant nerve damage (peripheral neuropathy) - You have uncontrolled infections or serious other illnesses - You are pregnant or breastfeeding - You have had prior brentuximab vedotin treatment Talk to your doctor to see if this trial is right for you.